首頁 > 市場調查報告書 > 製藥

感染疾病

市場調查報告書

商品編碼

1935339

結核病藥物市場按治療方法、疾病類型、分銷管道和地區分類

Tuberculosis Drugs Market, By Therapy Type, By Disease type, By End User , By Geography

出版日期: 2026年01月19日 | 出版商:

Coherent Market Insights | 英文 151 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到 2026 年，結核病治療藥物市場價值將達到 25.1 億美元，預計到 2033 年將達到 34.9 億美元，2026 年至 2033 年的複合年成長率為 4.77%。

報告覆蓋範圍		報告詳情
基準年：	2025	2026年市場規模：	25.1億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
預測期（2026-2033年）複合年成長率：	4.77%	2033 年的預測值：	34.9億美元

結核病是由結核分枝桿菌引起的常見感染疾病，主要侵犯肺部。結核病的治療分為第一線治療和二線治療。第一線治療包括使用異煙肼（INH）、利福平（RIF）、Pyrazinamide（PZA）、乙胺丁醇（EMB）和鏈黴素（SM）等藥物。然而，第一線治療對抗藥性結核病往往無效。結核病又分為潛伏期結核病和活動期結核病。

結核病的高發生率正在推動這一市場的成長。例如，根據世界衛生組織統計，2017年新增結核病病例中，有87%發生在結核病高發生的30個國家。在這30個國家中，印度、中國、印尼、菲律賓、巴基斯坦、奈及利亞、孟加拉和南非這8個國家的新增結核病病例佔總數的2/3。

市場動態

全球結核病負擔日益加重，預計將推動結核病治療市場成長。例如，根據美國疾病管制與預防中心（CDC）的數據，2017年全球共有1,000萬例結核病病例，130萬人死於結核病。

此外，根據世界衛生組織2018年發布的數據，結核病每年造成全球整體210億美元的損失，其中92億美元用於治療和預防，120億美元用於其他經濟損失和生產力損失。預計醫療保健領域結核病治療醫療費用支出的增加將推動市場成長。此外，據世界衛生組織稱，多重抗藥性結核病（MDR-TB）的治療週期為20至26個月，在美國的平均治療費用約為29.4萬美元。

此外，加大研發投入預計將推動市場成長。根據《2005-2017年結核病研究經費趨勢》報告，2017年全球結核病研究投資額為7.72億美元，較2016年的7.26億美元成長6%（4,600萬美元）。

本研究的主要特點：

本報告以 2025 年為基準年，對結核病治療市場規模（十億美元）和預測期（2026-2033 年）的複合年成長率進行了詳細分析。
它重點介紹了各個細分市場的潛在商機，並說明了該市場具有吸引力的投資提案矩陣。
該研究還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要企業採取的競爭策略的重要見解。
該報告根據公司概況、財務表現、產品系列、地理覆蓋範圍、關鍵發展和策略等參數，對全球結核病藥物市場的主要企業進行了概況介紹。
本報告的研究結果將使企業負責人和經營團隊能夠就產品發布、政府舉措、市場擴張和行銷策略做出明智的決策。
這份全球結核病治療市場報告的目標受眾是業內各種相關人員，包括投資者、產品製造商、經銷商、結核病治療供應商、研究和諮詢公司、新參與企業和金融分析師。

北美洲
- 美國
- 加拿大
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲
亞太地區
- 中國
- 日本
- 印度
- ASEAN
- 澳洲
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
非洲
- 北非
- 中非
- 南非
中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家

第8章競爭情勢

公司簡介
- Lupin ltd.
- Johnson &Johnson Services, LLC
- Novartis AG
- Macleods Pharmaceuticals Ltd.
- Otsuka Pharmaceutical Co., Ltd.
- Pfizer Inc.

第9章各節

參考
調查方法

簡介目錄

Product Code: CMI191

Tuberculosis Drugs Market is estimated to be valued at USD 2.51 Bn in 2026 and is expected to reach USD 3.49 Bn by 2033, growing at a compound annual growth rate (CAGR) of 4.77% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 2.51 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	4.77%	2033 Value Projection:	USD 3.49 Bn

Tuberculosis is a common infectious disease caused by mycobacterium tuberculosis that affects the lungs. The treatment of TB is divided into two types; first line therapy and second line therapy. In first line therapy, TB is treated with drugs such as isoniazid (INH), rifampin (RIF), pyrazinamide (PZA), ethambutol (EMB), and streptomycin (SM). However, first line therapy fails more often in the cases of drug resistant bacterial TB. Tuberculosis is classified into latent tuberculosis and active tuberculosis.

The high burden of TB is driving the growth of this market. For instance, according to the WHO, in 2017, 87% of new TB cases occurred in 30 high TB burden countries. The eight countries out of 30 include India, China, Indonesia, the Philippines, Pakistan, Nigeria, Bangladesh, and South Africa which accounted for two thirds of the new TB cases.

Market Dynamics

Increasing global burden of TB is expected to drive the tuberculosis drugs market growth. For instance, according to the Centre for Disease Control and Prevention, in 2017, 10.0 million people around the world suffered from TB, and there were 1.3 million TB-related deaths worldwide.

Moreover, according to WHO data published in 2018, TB costs the world over US$ 21 billion each year, including US$ 9.2 billion for treatment and prevention, and US$12 billion in additional economic costs and lost productivity. Increasing healthcare spending on treatment of TB is expected to drive growth of the market. Moreover, according to the WHO, treatment for multi-drug resistant TB (MDR-TB) takes 20-26 months, and average cost of treatment in the U.S. is around US$ 294,000.

Moreover, increasing investments in research and development activities are expected to drive growth of the market. According to the Tuberculosis Research Funding Trends 2005-2017 reports, global investment in TB research was valued at US$ 772 Million in 2017 with an increase of 6% (or US$ 46 million), compared to US$726 million in 2016.

Key features of the study:

This report provides in-depth analysis of the market, tuberculosis drugs market size (USD Bn), and compound annual growth rate (CAGR%) for the forecast period (2026 - 2033), considering 2025 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global tuberculosis drugs market based on the following parameters such as company overview, financial performance, product portfolio, geographical presence, key developments, and strategies
Key players covered as a part of this study include, include Johnson & Johnson Services, LLC, Lupin Ltd, Novartis AG, Macleods Pharmaceuticals Ltd., Otsuka Pharmaceutical Co., Ltd, Pfizer Inc., and others.
Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to product launches, governmental initiatives, market expansion, and marketing tactics
The global tuberculosis drugs market report caters to various stakeholders in this industry such as investors, product manufacturers, distributors, and suppliers of TB drugs, research and consulting firms, new entrants, and financial analysts

Market Segmentation

By Therapy Type,
- First Line Therapy
- Isoniazid (INH)
- rifampicin (RIF)
- Ethambutol (EMB)
- Pyrazinamide (PZA)
- Streptomycin (SM).
- Second Line Therapy
- Fluoroquinolones
- Injectable antituberculosis drugs
By Disease Type,
- Active TB
- Latent TB
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- Israel
- Rest of Middle East & Africa
Tuberculosis Drugs Market - Competitive Landscape
- Johnson & Johnson Services, LLC
- Lupin Ltd
- Novartis AG
- Macleods Pharmaceuticals Ltd.
- Otsuka Pharmaceutical Co., Ltd
- Pfizer Inc.

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Overview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Therapy Type
- Market Snippet, By Disease Type
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Key Developments
Regulatory Landscape
Drug Recall
Porter's Five Forces Model

4. Global Tuberculosis Drugs Market, By Therapy Type, 2026 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2017 - 2033
- Segment Trends
First Line Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Bn)
  - Isoniazid (INH)
  - rifampicin (RIF)
  - Ethambutol (EMB)
  - Pyrazinamide (PZA)
  - Streptomycin (SM)
Second Line Therapy
- Fluoroquinolones
- Injectable antituberculosis drugs

5. Global Tuberculosis Drugs Market, By Disease Type, 2026 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2017 - 2033
- Segment Trends
Active TB
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Bn)
Latent TB
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Bn)

6. Global Tuberculosis Drugs Market, By Distribution Channel, 2026 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2017 - 2033
- Segment Trends
Hospital Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Bn)
Retail Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Bn)
Online Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Bn)

7. Global Tuberculosis Drugs Market, By Region, 2026 - 2033, (USD Bn)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, By Region, 2018- 2033
- Regional Trends
North America
- Market Size and Forecast, By Therapy Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, By Disease Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026 - 2033, (USD Bn)
  - U.S.
  - Canada
Europe
- Market Size and Forecast, By Therapy Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, By Disease Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026 - 2033, (USD Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Market Size and Forecast, By Therapy Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, By Disease Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026 - 2033, (USD Bn)
  - China
  - Japan
  - India
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Latin America
- Market Size and Forecast, By Therapy Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, By Disease Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026 - 2033, (USD Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Africa
- Market Size and Forecast, By Therapy Type 2026 - 2033, (USD Bn)
- Market Size and Forecast, By Disease Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, By Country/Region, 2026 - 2033, (USD Bn)
  - North Africa
  - Central Africa
  - South Africa
Middle East
- Market Size and Forecast, By Therapy Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, By Disease Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026 - 2033, (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East

8. Competitive Landscape

Company Profiles
- Lupin ltd.
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Johnson & Johnson Services, LLC
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Novartis AG
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Macleods Pharmaceuticals Ltd.
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Otsuka Pharmaceutical Co., Ltd.
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Pfizer Inc.
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
  - Analyst Views